MITF depletion elevates expression levels of ERBB3 receptor and its cognate ligand NRG1-beta in melanoma

Tine N. Alver; Timothy J. Lavelle; Ane S. Longva; Geir F. Øy; Eivind Hovig; Sigurd L. Bøe

doi:10.18632/oncotarget.10422

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

MITF depletion elevates expression levels of ERBB3 receptor and its cognate ligand NRG1-beta in melanoma

Tine N. Alver _, Timothy J. Lavelle, Ane S. Longva, Geir F. Øy, Eivind Hovig and Sigurd L. Bøe

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:55128-55140. https://doi.org/10.18632/oncotarget.10422

Metrics: PDF 1815 views | HTML 4097 views | ?

Abstract

Tine N. Alver1, Timothy J. Lavelle1, Ane S. Longva1, Geir F. Øy1, Eivind Hovig1,2,3, Sigurd L. Bøe1

1Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway

2Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway

3Department of Informatics, University of Oslo, Oslo, Norway

Correspondence to:

Tine N. Alver, email: [email protected]

Keywords: MITF, ERBB3, NRG1-beta, PI3K signaling, melanoma

Received: March 11, 2016 Accepted: June 27, 2016 Published: July 06, 2016

ABSTRACT

The phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway is frequently hyper-activated upon vemurafenib treatment of melanoma. We have here investigated the relationship between SRY-box 10 (SOX10), forkhead box 3 (FOXD3) and microphthalmia-associated transcription factor (MITF) in the regulation of the receptor tyrosine-protein kinase ERBB3, and its cognate ligand neuregulin 1-beta (NRG1-beta). We found that both NRG1-beta and ERBB3 mRNA levels were elevated as a consequence of MITF depletion, induced by either vemurafenib or MITF small interfering RNA (siRNA) treatment. Elevation of ERBB3 receptor expression after MITF depletion caused increased activation of the PI3K pathway in the presence of NRG1-beta ligand. Together, our results suggest that MITF may play a role in the development of acquired drug resistance through hyper-activation of the PI3K pathway.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10422

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

MITF depletion elevates expression levels of ERBB3 receptor and its cognate ligand NRG1-beta in melanoma

Abstract